

# Rifaximin for the Secondary Prevention of Recurrent Pouchitis

NCT06312683

---

<b>Status</b>	RECRUITING
<b>Phase</b>	Phase 4
<b>Sponsor</b>	University of North Carolina, Chapel Hill
<b>Enrollment</b>	16 participants

## Key Eligibility Criteria

---

### Inclusion (4)

- Informed consent will be obtained before any study-related procedures
- Age  $\geq 18$  and  $\leq 75$  years
- Participants with a proven history of ulcerative colitis and history of 1,2, modified -2 or 3 stage Ileal pouch anal anastomosis (IPAA) and ileostomy takedown
- Diagnosis of initial episode of pouchitis within the first 12 months after ileostomy takedown/final stage of IPAA surgery

### Exclusion (20)

- Known hypersensitivity to rifaximin or its metabolites
- Known Crohn's disease
- History of perianal fistula
- Known incontinence due to anal sphincter dysfunction
- Known irritable pouch syndrome
- ... and 15 more (see full listing online)

## Locations (2 total)

---

NYU IBD Center, New York, New York, United States  
University of North Carolina, Chapel Hill, North Carolina, United States